308 related articles for article (PubMed ID: 17444888)
1. Impact of inflammation on epigenetic DNA methylation - a novel risk factor for cardiovascular disease?
Stenvinkel P; Karimi M; Johansson S; Axelsson J; Suliman M; Lindholm B; Heimbürger O; Barany P; Alvestrand A; Nordfors L; Qureshi AR; Ekström TJ; Schalling M
J Intern Med; 2007 May; 261(5):488-99. PubMed ID: 17444888
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum levels of S-adenosylhomocysteine, but not homocysteine, are associated with cardiovascular disease in stage 5 chronic kidney disease patients.
Valli A; Carrero JJ; Qureshi AR; Garibotto G; Bárány P; Axelsson J; Lindholm B; Stenvinkel P; Anderstam B; Suliman ME
Clin Chim Acta; 2008 Sep; 395(1-2):106-10. PubMed ID: 18565329
[TBL] [Abstract][Full Text] [Related]
3. Association between global leukocyte DNA methylation, renal function, carotid intima-media thickness and plasma homocysteine in patients with stage 2-4 chronic kidney disease.
Nanayakkara PW; Kiefte-de Jong JC; Stehouwer CD; van Ittersum FJ; Olthof MR; Kok RM; Blom HJ; van Guldener C; ter Wee PM; Smulders YM
Nephrol Dial Transplant; 2008 Aug; 23(8):2586-92. PubMed ID: 18287179
[TBL] [Abstract][Full Text] [Related]
4. Chronic kidney disease increases cardiovascular mortality in 80-year-old subjects in Japan.
Kagiyama S; Matsumura K; Ansai T; Soh I; Takata Y; Awano S; Sonoki K; Yoshida A; Takehara T; Iida M
Hypertens Res; 2008 Nov; 31(11):2053-8. PubMed ID: 19098377
[TBL] [Abstract][Full Text] [Related]
5. Excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients.
de Mutsert R; Grootendorst DC; Axelsson J; Boeschoten EW; Krediet RT; Dekker FW;
Nephrol Dial Transplant; 2008 Sep; 23(9):2957-64. PubMed ID: 18400817
[TBL] [Abstract][Full Text] [Related]
6. Muscle atrophy, inflammation and clinical outcome in incident and prevalent dialysis patients.
Carrero JJ; Chmielewski M; Axelsson J; Snaedal S; Heimbürger O; Bárány P; Suliman ME; Lindholm B; Stenvinkel P; Qureshi AR
Clin Nutr; 2008 Aug; 27(4):557-64. PubMed ID: 18538898
[TBL] [Abstract][Full Text] [Related]
7. Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients.
Suliman ME; Lindholm B; Bárány P; Qureshi AR; Stenvinkel P
Semin Dial; 2007; 20(6):523-9. PubMed ID: 17991198
[TBL] [Abstract][Full Text] [Related]
8. Global leukocyte DNA methylation is not altered in euthymic bipolar patients.
Bromberg A; Bersudsky Y; Levine J; Agam G
J Affect Disord; 2009 Nov; 118(1-3):234-9. PubMed ID: 19269035
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular biomarkers in CKD: pathophysiology and implications for clinical management of cardiac disease.
Roberts MA; Hare DL; Ratnaike S; Ierino FL
Am J Kidney Dis; 2006 Sep; 48(3):341-60. PubMed ID: 16931208
[TBL] [Abstract][Full Text] [Related]
10. Body mass index and mortality in CKD.
Madero M; Sarnak MJ; Wang X; Sceppa CC; Greene T; Beck GJ; Kusek JW; Collins AJ; Levey AS; Menon V
Am J Kidney Dis; 2007 Sep; 50(3):404-11. PubMed ID: 17720519
[TBL] [Abstract][Full Text] [Related]
11. Acute effect of simvastatin on inflammation and oxidative stress in chronic kidney disease.
Dummer CD; Thome' FS; Zingano B; Lindoso A; Veronese FV
J Nephrol; 2008; 21(6):900-8. PubMed ID: 19034875
[TBL] [Abstract][Full Text] [Related]
12. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.
Heinz J; Kropf S; Luley C; Dierkes J
Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080
[TBL] [Abstract][Full Text] [Related]
13. New insights on inflammation in chronic kidney disease-genetic and non-genetic factors.
Stenvinkel P
Nephrol Ther; 2006 Jul; 2(3):111-9. PubMed ID: 16890135
[TBL] [Abstract][Full Text] [Related]
14. Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study.
Panichi V; Rizza GM; Paoletti S; Bigazzi R; Aloisi M; Barsotti G; Rindi P; Donati G; Antonelli A; Panicucci E; Tripepi G; Tetta C; Palla R;
Nephrol Dial Transplant; 2008 Jul; 23(7):2337-43. PubMed ID: 18305316
[TBL] [Abstract][Full Text] [Related]
15. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP).
Bhuriya R; Li S; Chen SC; McCullough PA; Bakris GL
Am J Kidney Dis; 2009 Apr; 53(4 Suppl 4):S3-10. PubMed ID: 19285609
[TBL] [Abstract][Full Text] [Related]
16. Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease.
Kendrick J; Chonchol MB
Nat Clin Pract Nephrol; 2008 Dec; 4(12):672-81. PubMed ID: 18825155
[TBL] [Abstract][Full Text] [Related]
17. Telomere attrition is associated with inflammation, low fetuin-A levels and high mortality in prevalent haemodialysis patients.
Carrero JJ; Stenvinkel P; Fellström B; Qureshi AR; Lamb K; Heimbürger O; Bárány P; Radhakrishnan K; Lindholm B; Soveri I; Nordfors L; Shiels PG
J Intern Med; 2008 Mar; 263(3):302-12. PubMed ID: 18070000
[TBL] [Abstract][Full Text] [Related]
18. Low total plasma homocysteine level in relation to malnutrition, inflammation, and outcome in hemodialysis patients.
Akgul A; Bilgic A; Sezer S; Arat Z; Ozdemir FN; Haberal M
J Ren Nutr; 2008 Jul; 18(4):338-46. PubMed ID: 18558298
[TBL] [Abstract][Full Text] [Related]
19. "New" cardiovascular risk factors in patients with chronic kidney disease: role of folic acid treatment.
Bayés B; Pastor MC; Bonal J; Romero R
Kidney Int Suppl; 2005 Jan; (93):S39-43. PubMed ID: 15613067
[TBL] [Abstract][Full Text] [Related]
20. The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortality.
Suliman ME; Qureshi AR; Carrero JJ; Bárány P; Yilmaz MI; Snaedal-Jonsdottir S; Alvestrand A; Heimbürger O; Lindholm B; Stenvinkel P
QJM; 2008 May; 101(5):397-405. PubMed ID: 18292098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
